Christian Beisland (2268835)

Daniel Heinrich (158242)

Karin Hjelle (2268829)

Lars Akslen (4406518)

Leif Bostad (4406509)

Martin Pilskog (4406512)

OddbjĂ¸rn Straume (4406539)

Ăse Haug (4406536)

BMC Urology

FigShare

Additional file 4: Table S3. of Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma

Abstract Background Sunitinib has become mainstay first line treatment for patients with metastatic renal clear cell carcinoma (mRCC). Still, useful predictive markers of response are lacking and urgently needed for clinical decision making. Methods In the present study we investigated the predictive value of standard serum markers as well as clinical markers, including C-reactive protein (CRP), Neutrophil to Lymphocyte ratio (NLR) and early hypertension (eHTN) in an unselected prospective patient population treated with sunitinib for mRCC. Forty-six patients were enrolled in a prospective single-arm study of predictive markers for sunitinib response. Response rates according to RECIST 1.1 were used as primary end-point. Secondary objectives were to evaluate prognostic value of the candidate markers with regard to progression free survival (PFS) and overall survival (OS). In addition, toxicity rates and quality of life was recorded. Results Median PFS and OS was 9.1 months and 15.0 months, respectively. Of 38 patients evaluable for response, 1 patient had complete response (CR), 7 had partial response (PR), 18 had stable disease (SD) and 12 had progressive disease (PD). Normal CRP at baseline was significantly associated with objective response (CR + PR) (p = 0.01). Normal CRP was also significantly associated with improved PFS and OS (Log rank, p = 0.05 and <0.01, respectively). Early hypertension, NLR and IMDC risk score were not significantly associated with response rates or survival. Conclusion Baseline CRP was a significant predictive factor of sunitinib response and a prognostic factor of survival. Baseline CRP might be a useful biomarker in the treatment planning of mRCC. Due to the relatively small sample size, our results need to be confirmed in larger studies

Martin Pilskog

Christian Beisland

Lars A. Akslen

Leif Bostad

Åse Haug

Daniel Heinrich

Karin M. Hjelle

Oddbjørn Straume

Directory of Open Access Journals

Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma

Crossref

Åse Haug (4406515)

Oddbjørn Straume (158247)

Additional file 2: Table S1. of Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma

Background
Sunitinib has become mainstay first line treatment for patients with metastatic renal clear cell carcinoma (mRCC). Still, useful predictive markers of response are lacking and urgently needed for clinical decision making.

Methods
In the present study we investigated the predictive value of standard serum markers as well as clinical markers, including C-reactive protein (CRP), Neutrophil to Lymphocyte ratio (NLR) and early hypertension (eHTN) in an unselected prospective patient population treated with sunitinib for mRCC. Forty-six patients were enrolled in a prospective single-arm study of predictive markers for sunitinib response. Response rates according to RECIST 1.1 were used as primary end-point. Secondary objectives were to evaluate prognostic value of the candidate markers with regard to progression free survival (PFS) and overall survival (OS). In addition, toxicity rates and quality of life was recorded.

Results
Median PFS and OS was 9.1 months and 15.0 months, respectively. Of 38 patients evaluable for response, 1 patient had complete response (CR), 7 had partial response (PR), 18 had stable disease (SD) and 12 had progressive disease (PD). Normal CRP at baseline was significantly associated with objective response (CR + PR) (p = 0.01). Normal CRP was also significantly associated with improved PFS and OS (Log rank, p = 0.05 and <0.01, respectively). Early hypertension, NLR and IMDC risk score were not significantly associated with response rates or survival.

Conclusion
Baseline CRP was a significant predictive factor of sunitinib response and a prognostic factor of survival. Baseline CRP might be a useful biomarker in the treatment planning of mRCC. Due to the relatively small sample size, our results need to be confirmed in larger studies.publishedVersio

Pilskog, Martin

Beisland, Christian

Akslen, Lars A

Bostad, Leif

Haug, Åse

Heinrich, Daniel

Hjelle, Karin Margrethe

Straume, Oddbjørn

ODA Open Digital Archive (Oslomet)

Correlations between CRP and other variables. (DOCX 15 kb

Additional file 3: Table S2. of Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma

Background
Sunitinib has become mainstay first line treatment for patients with metastatic renal clear cell carcinoma (mRCC). Still, useful predictive markers of response are lacking and urgently needed for clinical decision making.

Methods
In the present study we investigated the predictive value of standard serum markers as well as clinical markers, including C-reactive protein (CRP), Neutrophil to Lymphocyte ratio (NLR) and early hypertension (eHTN) in an unselected prospective patient population treated with sunitinib for mRCC. Forty-six patients were enrolled in a prospective single-arm study of predictive markers for sunitinib response. Response rates according to RECIST 1.1 were used as primary end-point. Secondary objectives were to evaluate prognostic value of the candidate markers with regard to progression free survival (PFS) and overall survival (OS). In addition, toxicity rates and quality of life was recorded.

Results
Median PFS and OS was 9.1 months and 15.0 months, respectively. Of 38 patients evaluable for response, 1 patient had complete response (CR), 7 had partial response (PR), 18 had stable disease (SD) and 12 had progressive disease (PD). Normal CRP at baseline was significantly associated with objective response (CR + PR) (p = 0.01). Normal CRP was also significantly associated with improved PFS and OS (Log rank, p = 0.05 and <0.01, respectively). Early hypertension, NLR and IMDC risk score were not significantly associated with response rates or survival.

Conclusion
Baseline CRP was a significant predictive factor of sunitinib response and a prognostic factor of survival. Baseline CRP might be a useful biomarker in the treatment planning of mRCC. Due to the relatively small sample size, our results need to be confirmed in larger studies

NORA - Norwegian Open Research Archives

https://figshare.com/articles/Additional_file_3_Table_S2_of_Predictive_value_of_C-reactive_protein_in_patients_treated_with_sunitinib_for_metastatic_clear_cell_renal_cell_carcinoma/5368066

Additional file 4: Table S3. of Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma

Abstract

Similar works

Full text

Available Versions

FigShare

Directory of Open Access Journals

Crossref

FigShare

ODA Open Digital Archive (Oslomet)

FigShare

NORA - Norwegian Open Research Archives